二肽基肽酶-4抑制剂在我国2型糖尿病全程管理中的应用

Use of dipeptidyl peptidase Ⅳ inhibitor in the comprehensive management of type 2 diabetes mellitus in Chinese population

中国糖尿病治疗领域面临严峻挑战,需要新的治疗手段进行全面管理.二肽基肽酶Ⅳ(DPP-4)抑制剂可改善胰岛细胞功能,促进胰岛素分泌,抑制胰高血糖素分泌,并且不增加低血糖发生和体重增加的风险.无论是饮食、运动控制不佳的基础上单药治疗,或是与二甲双胍、磺脲类药物、噻唑烷二酮类药物或胰岛素联合应用,DPP-4抑制剂均能持续有效地降低糖化血红蛋白、空腹和餐后血糖.DPP-4抑制剂与二甲双胍早期联合,在治疗机制上互补,成为2型糖尿病治疗的理想方案.本文对DPP-4抑制剂在治疗中国2型糖尿病人群的疗效和安全性研究进展做简要综述.

Currently, China still faces tremendous challenges in the field of diabetes treatment and control, and new treatments are needed for comprehensive management of patients with type 2 diabetes mellitus. Dipeptidyl peptidase IV（DPP-4） inhibitors can improve islet cell function, promote the secretion of insulin and inhibit the secretion of glucagon, without increased risks of hypoglycemia and weight gain. DPP-4 inhibitors, regardless of monotherapy or in combination with other anti-hyperglycemic medication or insulin, can effectively reduce glycated hemoglobin（Hb A1 c）, fasting and postprandial blood glucose in poorly controlled type 2 diabetes. The early combination of DPP-4 inhibitor with metformin, by complementing each other in the therapeutic mechanism, is an ideal therapeutic strategy for diabetes treatment. This article briefly reviews the efficacy and safety of DPP-4 inhibitors in the treatment of type 2 diabetes in Chinese population.